Site of pneumonia on HRCT.

<p>Site of pneumonia on HRCT.</p

Bacteria causing pulmonary infections in patients with IPF.

<p>Bacteria causing pulmonary infections in patients with IPF.</p

Characteristics of patients during the first admission following IPF diagnosis.

<p>Characteristics of patients during the first admission following IPF diagnosis.</p

Univariate logistic regression analysis for hospital mortality during first admission following IPF diagnosis.

<p>Univariate logistic regression analysis for hospital mortality during first admission following IPF diagnosis.</p

Aerosol Deposition of Inhaled Corticosteroids/Long-Acting β2-Agonists in the Peripheral Airways of Patients with Asthma Using Functional Respiratory Imaging, a Novel Imaging Technology

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s41030-017-0036-4">https://link.springer.com/article/10.1007/s41030-017-0036-4</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes

<div><p>Aims/Hypothesis</p><p>Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.</p><p>Methods</p><p>First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).</p><p>Results</p><p>Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.</p><p>Conclusion/Interpretation</p><p>The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.</p></div

Clinical characteristics of the subjects.

<p>Clinical characteristics of the subjects.</p

Titres of anti- LGALS3 antibody in sera, as determined by ELISA.

<p>Graph shows the titres of anti-LGALS3 antibody in sera from patients with fulminant type 1 diabetes in the acute phase (FT1D, A: n = 14), FT1D in the sub-acute phase (FT1D, SA: n = 14), type 1 diabetes (T1AD: n = 32), type 2 diabetes (T2D: n = 30), autoimmune thyroid disease (AITD: n = 22) and healthy control subjects (HC: n = 31). The bars indicate the mean.</p

Clinical characteristics of 3 patients with fulminant type 1 diabetes in seromic analysis.

<p>Clinical characteristics of 3 patients with fulminant type 1 diabetes in seromic analysis.</p

ROC analysis of anti-CD300e antibody.

<p>A: ROC analysis of patients with FT1D in the acute phase (n = 26) and HC (n = 30). B: ROC analysis of patients with FT1D in the acute phase (n = 26) and T1AD (n = 32).</p